SUPERNUS PHARMACEUTICALS, INC. SUPN

About SUPERNUS PHARMACEUTICALS, INC. (SUPN): stock profile, AI score and financials

SUPERNUS PHARMACEUTICALS, INC. (SUPN) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SUPN at 41.2/100 on a composite quality score built from its SEC filings, placing it at rank #2,055 of 2,925 stocks — the bottom half of the AI-ranked universe. Areas of concern include profitability (16.8) and balance sheet strength (18.8), which score below median versus the broader universe. Shareholder dilution risk is elevated at 25.5/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), SUPERNUS PHARMACEUTICALS, INC. reports quarterly revenue of $219.1M, net income of $-58.4M, an operating margin of -26.5%. Top institutional holders of SUPN by reported 13-F value include BlackRock, MILLENNIUM MANAGEMENT, VANGUARD PORTFOLIO MANAGEMENT, based on the most recent SEC filings. SUPN trades on the Nasdaq exchange and files with the SEC under CIK 1356576. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SUPN daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for SUPERNUS PHARMACEUTICALS, INC. directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1356576 →